Fact-checked by Grok 2 weeks ago

Vitrectomy

Vitrectomy is a microsurgical in which an ophthalmologist removes some or all of the vitreous humor—the clear, gel-like substance that fills the space between the and the in the eye—to address disorders affecting the or vitreous itself. This surgery provides access to the posterior segment of the eye, allowing the surgeon to repair damage, remove , or alleviate traction on the . Commonly performed on an outpatient basis under local or general , vitrectomy involves small incisions in the , typically through the region, to insert specialized instruments that cut and aspirate the vitreous while infusing a to maintain eye . The procedure is most frequently indicated for conditions such as , where vitreous hemorrhage or tractional abnormalities obscure vision or threaten the ; , in which the vitreous is removed along with any fibrovascular tissue pulling on the ; macular holes or epiretinal membranes that distort central vision; and severe vitreous opacities like or infections. During , additional interventions may include photocoagulation or to seal retinal tears, membrane peeling to relieve traction, and injection of a gas bubble, , or air to the and promote reattachment. Modern techniques often employ microincision vitrectomy (MIVS) with 23-, 25-, or 27-gauge instruments, minimizing trauma and enabling sutureless closure for faster recovery. While vitrectomy has significantly improved outcomes for complex vitreoretinal diseases—restoring or preserving vision in many cases—it carries potential risks including infection, bleeding, increased , formation (common in phakic eyes, especially those over 50), recurrent , and rare vision loss. Recovery typically spans 2 to 6 weeks, with patients advised to avoid strenuous activity, wear an eye shield, and position their head face-down if a gas is used to ensure proper retinal positioning. Postoperative care involves and eye drops, frequent follow-up examinations, and monitoring for complications, with most individuals experiencing gradual improvement in .

Overview

Definition and Purpose

Vitrectomy is a microsurgical procedure that involves the removal of the vitreous humor, the transparent, gel-like substance filling the posterior segment of the eye, to address various vitreoretinal conditions. The vitreous humor consists primarily of (approximately 99%), with a structural framework provided by fibrils and , which together form a viscoelastic gel that helps maintain the eye's spherical shape, supports optical clarity, and cushions the . This avascular, acellular matrix occupies about four-fifths of the eye's volume, extending from the to the and . The primary purpose of vitrectomy is to restore or improve visual function by eliminating pathological elements within the vitreous that impair light transmission or exert mechanical stress on structures. Common therapeutic goals include clearing vitreous opacities, such as hemorrhage or inflammatory debris, relieving tractional forces that can lead to or , and enabling interventions for reattachment in conditions like proliferative or rhegmatogenous detachment. By excising diseased vitreous tissue, the procedure creates a clearer optical pathway and reduces the risk of further damage, often resulting in enhanced and for affected patients. Following removal, the vitreous cavity is typically filled with a temporary substitute—such as for immediate support, intravitreal gas for during retinal repair, or for longer-term stabilization—to preserve and facilitate healing. Unlike , a method that uses ultrasonic energy to emulsify and aspirate the opaque crystalline lens in the anterior segment, vitrectomy is directed at the posterior segment to manage disorders involving the vitreous and .

Historical Development

The earliest attempts at vitreous surgery date back to the , when Dutch anatomist Anton Nuck performed the first recorded removal of vitreous humor in cases of hydrophthalmia (congenital ) to reduce , though these were limited to experimental procedures on animal models and did not achieve clinical success in humans. In the , American surgeon conducted one of the first human trials of vitrectomy in the 1840s, attempting to remove dislocated crystalline lenses and vitreous opacities, but outcomes were poor due to rampant postoperative infections and lack of sterile techniques, leading to high rates of and vision loss. These pioneering efforts, including pars plana incisions by Albrecht von Graefe in 1863 to cut vitreous membranes in hemorrhagic or detached retinas, laid rudimentary groundwork but were constrained by inadequate visualization tools like the ophthalmoscope introduced by in 1851. Advancements accelerated in the mid-20th century amid growing interest in vitreoretinal surgery for conditions like vitreous hemorrhage and . In the and , open-sky techniques emerged, with Tsugio Dodo using scissors for vitreous removal in and David Kasner refining cellulose sponge vitrectomy in 1965 to address vitreous loss during , though these methods risked corneal exposure and contamination. The pivotal breakthrough came in 1970 when Robert Machemer, with contributions from Jean-Marie Parel and others, invented the vitrectomy using a 17-gauge multifunctional cutter, fiberoptic illumination, and a closed-eye system to minimize infection risks, marking the birth of modern vitreoretinal subspecialty and enabling safer posterior segment access. This innovation was quickly advanced in 1971 by Gholam with the Vitrophage instrument incorporating a three-mirror for better . The 1970s saw further refinement with the introduction of the three-port, 20-gauge system in 1972 by Conor O'Malley and Ralph , utilizing the Ocutome console for separate , , and illumination ports, which improved surgical control and efficiency. By 1983, Steve Charles and Carl Wang developed the first disposable, single-pulse vitreous cutter, enhancing cutting precision and reducing tissue trauma. The 2000s ushered in microincision vitrectomy (MIVS), with Eugene de pioneering sutureless 25-gauge transconjunctival vitrectomy in 2002 for less invasive procedures, followed by 23-gauge systems from Claus Eckardt in 2005 and 27-gauge by Yusuke Oshima in 2010, allowing smaller incisions, faster recovery, and fewer complications like . Post-2000 milestones included the widespread adoption of wide-angle viewing systems, such as the BIOM (binocular indirect ophthalmo-microscope) introduced by in 1987 but popularized around 2005 for panoramic fundus visualization up to 130 degrees, and chandelier endoillumination systems enabling bimanual surgery without assistant-held lights. Recent developments since 2021 have integrated intraoperative (iOCT) for real-time tissue imaging during vitrectomy, with 2023 studies demonstrating improved decision-making in repairs and peels by providing micron-level and reducing incomplete surgeries. Additionally, AI-assisted planning has emerged, as shown in 2023 research using to analyze preoperative images for personalized surgical strategies in vitreoretinal cases, predicting outcomes and optimizing instrument trajectories to enhance precision. As of 2025, further innovations include robotic assistance for enhanced precision in vitreoretinal procedures, high-speed vitrectomy cutters reaching 25,000 cuts per minute with beveled tips for improved efficiency, and advanced dual-blade systems enabling continuous aspiration and flow, alongside expanded applications of iOCT in complex cases.

Indications

Primary Indications

Vitrectomy, specifically pars plana vitrectomy (PPV), serves as the standard surgical intervention for several sight-threatening vitreoretinal conditions where the vitreous body's involvement exacerbates pathology. Primary indications encompass scenarios in which vitreous opacification, traction, or hemorrhage impairs visualization or function, necessitating removal to restore anatomical integrity and . These indications are guided by clinical evidence from large-scale studies and expert consensus, focusing on cases unresponsive to . Rhegmatogenous retinal detachment (RRD), characterized by retinal tears allowing subretinal fluid accumulation, is a core indication for PPV, particularly when posterior vitreous detachment contributes to tear formation or when multiple breaks or proliferative vitreoretinopathy complicates repair. Tractional retinal detachment (TRD), often driven by fibrovascular proliferation pulling on the retina, also warrants PPV to relieve vitreous adhesions and reattach the retina, especially in cases involving the macula. While exudative detachments are typically managed medically, PPV may be indicated if vitreous traction secondary to underlying inflammation or neoplasm plays a contributory role. In proliferative diabetic retinopathy (PDR), PPV is indicated for persistent vitreous hemorrhage obscuring the fundus view beyond 4-6 weeks despite laser therapy, or for TRD threatening the due to neovascular traction. These interventions aim to clear hemorrhage and dissect preretinal membranes, with studies showing favorable anatomical success rates in advanced PDR stages. Macular disorders such as (macular pucker), a fibrocellular on the surface causing distortion, and full-thickness macular s, idiopathic or traction-induced defects in the fovea, represent key indications where PPV facilitates membrane peeling and hole closure to alleviate and improve central vision. Non-clearing vitreous hemorrhage from diverse etiologies, including ocular trauma, retinal vein occlusion, or intraocular tumors, is another primary indication for PPV when bleeding persists for over one month and impedes retinal assessment or causes significant . In the United States, these primary indications account for over 225,000 PPV procedures annually, reflecting the high burden of vitreoretinal diseases in aging and diabetic populations. Recent advancements recognize PPV for severe symptomatic vitreous syneresis, particularly in highly myopic patients experiencing vision-degrading myodesopsia (VDM) from dense that substantially reduce contrast sensitivity and ; recent studies and clinical discussions support this for cases to , emphasizing patient-reported symptom severity in selection.

Patient Selection Criteria

Patient selection for vitrectomy involves a comprehensive assessment of clinical factors to determine suitability, weighing potential benefits against risks, particularly in conditions like proliferative diabetic retinopathy (PDR) or . Key evaluation factors include baseline , which guides ; for instance, eyes with useful (e.g., better than light perception) in severe PDR show improved outcomes with early intervention, as demonstrated by the Diabetic Retinopathy Vitrectomy Study (DRVS) where 25% of early vitrectomy patients achieved 20/40 or better at two years compared to 15% in deferred cases. Duration of symptoms is also critical; in patients with severe vitreous hemorrhage, vitrectomy within 1-6 months reduces severe visual loss risk, whereas patients may not benefit as significantly from early surgery. Comorbidities, such as uncontrolled diabetes, , renal disease, or cardiovascular conditions, elevate perioperative risks, including higher long-term mortality (up to 48.7% over 10 years in diabetic tractional cases) and postoperative complications like recurrent hemorrhage. There are no absolute contraindications to vitrectomy (PPV), but relative contraindications include eyes with no light perception vision, indicating minimal visual potential (e.g., due to optic ), where offers little benefit and carries undue risk. Poor general health precluding safe , such as severe cardiopulmonary , also weighs against proceeding, as systemic comorbidities can amplify intraoperative and postoperative risks. In cases of poorly adhesive intraocular tumors like , vitrectomy risks dissemination and is relatively contraindicated. Preoperative imaging and tests are essential for planning and confirming suitability. Optical coherence tomography (OCT) evaluates macular status, vitreoretinal interface, and potential for anatomical restoration in conditions like tractional or macular holes. Fundus photography documents retinal lesions, vascular abnormalities, and baseline findings for postoperative comparison. B-scan ultrasound is particularly valuable when media opacities (e.g., vitreous hemorrhage) obscure visualization, assessing extent, vitreous adhesions, and posterior structures. For hereditary vitreoretinopathies, such as familial exudative vitreoretinopathy (FEVR), is recommended if clinical suspicion arises (e.g., peripheral avascular ), to confirm diagnosis and inform surgical timing, as variants in genes like or FZD4 influence progression and intervention needs. Shared decision-making is integral, involving discussion of vitrectomy benefits (e.g., vision stabilization in PDR) against risks (e.g., , ) and alternatives like observation, laser therapy, or injections for less severe cases, ensuring alignment with patient values and preferences. Emerging options, such as low-dose atropine (as of 2025), may provide symptomatic relief for and influence decisions for surgical intervention in select cases. This process, emphasized in AAO guidelines, particularly aids in elective scenarios where outcomes vary by individual factors.

Preoperative Preparation

Patient Evaluation

Patient evaluation prior to vitrectomy involves a multifaceted assessment to determine the suitability of the procedure, identify potential risks, and optimize outcomes. This process begins with a comprehensive ophthalmic examination, which includes visual acuity testing, slit-lamp biomicroscopy to evaluate the anterior and posterior segments, fundus examination for retinal pathology, and intraocular pressure measurement. Tonometry and indirect ophthalmoscopy are essential to assess the extent of vitreoretinal disease, such as retinal detachment or vitreous hemorrhage, ensuring that the underlying condition warrants surgical intervention. Gonioscopy is routinely performed to examine the anterior chamber angle, particularly in cases of proliferative or trauma, to rule out or angle abnormalities that could complicate surgery. If vitrectomy is combined with extraction or (IOL) implantation, biometry using or methods is conducted to calculate the appropriate IOL power, minimizing postoperative refractive errors. Advanced imaging modalities, such as (OCT), provide detailed cross-sectional views of the and vitreous, aiding in precise preoperative planning; for instance, wide-field OCT can delineate macular involvement in epiretinal membranes. Evaluations follow guidelines from organizations like the (AAO), ensuring comprehensive assessment. Systemic evaluation is equally critical to ensure patient stability under and . This includes a complete review, focusing on cardiovascular, pulmonary, and hematologic conditions, followed by laboratory tests such as , coagulation profile, and blood glucose levels to screen for , bleeding disorders, or uncontrolled . Cardiac clearance, often via electrocardiogram or consultation with a cardiologist, is recommended for patients with known heart disease, while infection screening—such as and —helps prevent complications. In elderly patients or those with comorbidities, pulmonary function tests may be indicated to assess respiratory risks. The process is a cornerstone of evaluation, where the discusses the procedure's indications, expected benefits, potential risks (including , retinal tears, and formation), and alternatives such as observation or laser therapy. This conversation is documented, with emphasis on realistic outcomes based on the 's specific , and is tailored to address concerns for shared . Timing of evaluation varies by condition urgency; for progressive retinal detachments, is expedited within hours to days to preserve vision, whereas chronic conditions like macular holes allow for elective scheduling over weeks. Recent advancements enhance preoperative precision. AI predictive modeling, leveraging machine learning on retinal scans, has emerged in research from 2023 to 2025 to forecast postoperative visual outcomes and complication risks, with models achieving accuracies around 80-85% in predicting success for conditions like retinal detachment repair.

Anesthesia and Preparation

Vitrectomy procedures typically employ as the primary method for adult patients, with options including retrobulbar, peribulbar, and sub-Tenon's blocks to achieve analgesia and akinesia while minimizing systemic s. Retrobulbar involves an intraconal injection of 4-5 mL of anesthetic, providing rapid onset but carrying a of globe (approximately 0.9 per 10,000 cases). Peribulbar blocks use extraconal injections of 5-10 mL, offering a slower onset and lower (about 1 per 16,000 cases) but potentially causing . Sub-Tenon's , administered into the subconjunctival space, is increasingly preferred in recent practices (2023-2025) for its safer profile, reduced of , and comparable analgesia to peribulbar methods, though it may provide less complete akinesia. Local approaches reduce postoperative and shorten recovery compared to general , which is reserved for pediatric patients, uncooperative adults, or complex cases requiring absolute immobility. Sedation is often supplemented with monitored anesthesia care (MAC) using intravenous agents like for anxious patients undergoing local blocks, allowing patient communication while avoiding full general . For minimally invasive vitrectomies, such as those using 23- or 25-gauge systems, topical or intracameral (e.g., lidocaine) may suffice, offering simplicity but limited duration for longer procedures. General , involving agents like , ensures controlled unconsciousness but increases costs, recovery time, and risks of intraocular pressure spikes. Preoperative preparation begins with pupil dilation using mydriatic drops (e.g., tropicamide and ) to facilitate surgical access, typically administered 30-60 minutes prior. Antibiotic prophylaxis involves topical application of 5% to the ocular surface, with systemic antibiotics generally avoided in routine cases to prevent . The patient is positioned with head stabilization, the operative eye cleaned with , and sterile draping applied to maintain a sterile field; an speculum keeps the eye open. Intraoperative monitoring includes continuous (e.g., , ECG, ) and intraocular pressure tracking to manage fluctuations, which can reach 120 mm during vitrectomy. Procedures last 1-3 hours depending on complexity.

Surgical Procedure

Types of Vitrectomy

Vitrectomy procedures are categorized primarily by their surgical access and the extent of vitreous removal, ranging from limited anterior interventions to comprehensive posterior segment approaches. These variations allow tailored treatment for specific vitreoretinal pathologies, balancing invasiveness with efficacy. Anterior vitrectomy involves the limited removal of vitreous humor from the anterior chamber and anterior vitreous, typically accessed through a pars plana incision. It is primarily indicated following complications during cataract surgery, such as posterior capsule rupture leading to vitreous prolapse or dropped lens fragments, to prevent traction on the retina and reduce the risk of cystoid macular edema. This technique focuses on clearing vitreous strands from the anterior segment without extensive posterior involvement, preserving the integrity of the posterior vitreous face. The standard procedure for posterior segment disorders is pars plana vitrectomy (PPV), which provides access to the vitreous cavity and through small scleral ports placed at the , approximately 3-4 mm posterior to the limbus. Developed by Robert Machemer in 1971 as a closed-system technique, PPV enables the removal of vitreous opacities, relief of traction, and repair of retinal issues like detachments, macular holes, and vitreous hemorrhages. It typically employs a three-port system for infusion, illumination, and vitreoretinal instruments, making it the cornerstone for most vitreoretinal surgeries. Minimally invasive vitrectomy (MIVS) represents advanced variants of PPV using smaller instruments—23- (0.64 mm incision), 25- (0.51 mm), and 27- (0.4 mm)—to create self-sealing, sutureless sclerotomies. Introduced starting in 2002 with 25- systems and advancing post-2005, these systems reduce conjunctival dissection, minimize postoperative (e.g., by up to 0.5 diopters less than 20-), and shorten time through decreased inflammation and faster . They are particularly suited for less complex cases like epiretinal membranes or macular holes, offering comparable anatomical success rates to traditional methods while enhancing comfort. Combined procedures integrate PPV with other interventions to address multifocal pathology in a single session. PPV combined with and implantation is common in phakic patients with rhegmatous , improving peripheral visualization for complete vitreous removal and achieving anatomical repair rates around 93%. Similarly, PPV with scleral buckling applies external indentation to relieve vitreoretinal traction in high-risk detachments, particularly inferior breaks, reducing recurrence risk without significantly increasing complications. These combinations optimize outcomes by tackling coexisting anterior and posterior issues concurrently. The evolution of vitrectomy has progressed from the original 20-gauge sutured system, which dominated until the early , to smaller-gauge sutureless techniques emerging starting in 2002. The 25-gauge system, introduced in 2002, pioneered transconjunctival sutureless vitrectomy, followed by the 23-gauge system in 2005, which bridged the gap by balancing rigidity and minimal invasiveness, and the 27-gauge system around 2010, driven by improvements in cutter speeds and . This shift has minimized surgical trauma, with sutureless approaches now standard for over 80% of cases, leading to reduced operative times and lower rates of . As of 2025, robotic-assisted PPV is an emerging trend enhancing precision in vitreoretinal surgery, with systems like the PRECEYES Surgical System achieving sub-10-micrometer accuracy for tasks such as internal limiting membrane peeling. These platforms, approved in regions like the EU since 2019, enable tremor-free bimanual operations and have demonstrated safety in clinical trials for proliferative . Ongoing advancements include first-in-human trials of systems like the robotic platform as of mid-2025, potentially reducing intraoperative complications and expanding access for complex cases.

Instruments and Techniques

Vitrectomy relies on specialized instruments designed for minimally invasive access to the vitreous cavity, typically through small-gauge (23-, 25-, or 27-gauge) sclerotomy ports to reduce and enhance recovery. The core instrument is the vitreous cutter, a guillotine-style probe that simultaneously cuts and aspirates vitreous gel, operating at cut rates of 500 to 6,000 cuts per minute depending on the gauge and system, allowing precise removal without excessive traction on structures. Complementary tools include the endoilluminator, a fiberoptic pipe inserted via a separate port to provide intraoperative illumination of the posterior segment, and the infusion cannula, which maintains by delivering throughout the procedure. Advanced instruments expand surgical capabilities for complex maneuvers. lights offer hands-free illumination by securing a fiberoptic source to the , freeing both surgeon hands for instrumentation and improving maneuverability during membrane peeling or peripheral work. and microscissors, available in fine-tipped designs compatible with small-gauge systems, enable delicate and excision of epiretinal or internal limiting membranes. probes facilitate endolaser photocoagulation for treating retinal breaks or directly within the vitreous cavity, integrating with the vitrectomy system for targeted energy delivery. Key techniques optimize vitreous removal and cavity management. Core vitrectomy involves bulk aspiration of central vitreous gel using the to debulk the and gain access to posterior . Peripheral employs scleral and the to meticulously remove vitreous skirt at the base, minimizing traction and reducing recurrence risk in conditions like . Air-fluid exchange is performed via extrusion cannulas to replace vitreous cavity fluids with air or gas tamponades, aiding in fluid management, subretinal drainage, and bubble positioning for retinal reattachment. Visualization systems are integral for wide-field assessment during . systems, such as indirect aspheric lenses, provide a fixed up to 120 degrees when placed on the , offering high-resolution central and peripheral imaging. Non-contact viewing systems, mounted on the surgical , enable adjustable wide-angle observation without corneal distortion, allowing dynamic eye movement and reduced induction. Recent innovations from 2023 to 2025 have enhanced precision and ergonomics. Three-dimensional heads-up surgery systems project a stereoscopic image onto a high-definition , reducing reliance on eyepieces, minimizing fatigue, and providing stable illumination with lower risk compared to traditional . These systems integrate with existing vitrectomy platforms for comparable anatomical outcomes in procedures.

Step-by-Step Execution

The vitrectomy (PPV) procedure begins with the creation of three sclerotomies in the region, typically 3.5 to 4 mm posterior to the limbus in phakic eyes or 3 mm in pseudophakic eyes, to establish access ports for , illumination, and the vitrectomy cutter. These ports are created using a 23-, 25-, or 27-gauge trocar-cannula system, with the port placed inferotemporally to maintain , the light port superotemporally for chandelier illumination, and the instrument port superonasally for the cutter. Following port placement, core vitrectomy is performed to remove the central vitreous gel, using a high-speed vitrectomy probe that combines cutting and functions, typically set at 2,500 to 5,000 cuts per minute to minimize traction on surrounding tissues. may be injected to enhance of the vitreous, particularly in cases of hemorrhage or incomplete opacification. Next, separation of the posterior hyaloid membrane is induced if it remains adherent, often by applying over the with the cutter in a non-cutting mode, followed by gentle elevation and removal to relieve vitreoretinal traction. Adjunctive steps are then tailored to the underlying , including membrane peeling with microforceps and vital dyes such as brilliant G to remove epiretinal or internal limiting membranes, endolaser photocoagulation to seal retinal breaks, and with expansile gas (e.g., or perfluoropropane) or to support retinal reattachment. In contemporary protocols, intraoperative (iOCT) is integrated to provide real-time imaging of retinal layers, guiding precise adjustments such as confirming complete removal or identifying subtle traction during peeling, thereby enhancing surgical accuracy without additional dyes in select cases. The concludes with removal of the trocars and closure of sclerotomies; smaller-gauge systems (25- or 27-gauge) often seal spontaneously due to self-sealing properties, while larger 20-gauge ports may require sutures with 8-0 or 9-0 polyglactin. Overall duration typically ranges from 45 to 120 minutes, with extensions for combined procedures such as extraction or to address concurrent anterior segment or retinal support needs.

Complications

Intraoperative Risks

Intraoperative bleeding in vitrectomy primarily arises from iatrogenic damage to retinal vessels, often during dissection of fibrovascular membranes in proliferative cases. This complication can obscure visualization and prolong surgery, with management involving immediate elevation of via the infusion line to achieve , followed by endodiathermy (cautery) for vessel or addition of hemostatic agents such as dilute epinephrine to the infusion fluid. In severe instances, photocoagulation may be applied intraoperatively to seal leaking vessels. Instrument-related issues pose additional risks, including inadvertent touch by vitrectomy probes or illumination devices, which accelerates formation in phakic eyes. The incidence of lens touch is approximately 0.9% in experienced hands, though higher among trainees, and typically results in posterior capsule opacification requiring subsequent . Another concern is infusion overpressure, which can cause anterior chamber shallowing or collapse if the dislodges or pressure exceeds physiological limits, potentially leading to or corneal touch; this is mitigated by continuous monitoring of bottle height and . Iatrogenic retinal tears occur in about 5-10% of vitrectomy procedures, most commonly during posterior hyaloid or peeling due to tangential traction on the retinal surface. Peripheral tears linked to sclerotomy sites are reported at 4%, while posterior breaks reach 6%, with higher rates in 20-gauge systems compared to smaller-gauge vitrectomies (7.9% versus 1.7%). These tears are promptly addressed with endolaser retinopexy or to prevent . Anesthesia-related intraoperative risks, though rare, include ocular perforation from retrobulbar or peribulbar blocks, with an incidence of less than 1% (0.08-0.71%, elevated in high ). Perforation often causes vitreous hemorrhage in up to 85% of cases and in nearly 50%, necessitating immediate vitrectomy if visualization is compromised. Mitigation strategies emphasize real-time monitoring using wide-field viewing systems and intraoperative (iOCT) to enhance tissue visualization and reduce error rates. Surgeon experience significantly lowers complication incidence, with studies showing decreased iatrogenic breaks in high-volume operators. Emerging robotic systems, such as the iArmS and PRECEYES, further reduce intraoperative errors by 32-52% through suppression and micron-level precision during tasks like membrane peeling, as demonstrated in 2025 reviews.

Postoperative Complications

Postoperative complications following vitrectomy can range from mild and transient to severe, potentially impacting visual outcomes and requiring additional interventions. These issues often arise due to surgical trauma, intraocular tamponade agents like gas or , , or , with early detection through regular follow-up examinations crucial for management. Incidence rates vary based on patient factors such as age, underlying retinal , and surgical technique, but advancements in have helped mitigate some risks. Cataract progression is one of the most frequent complications, particularly in phakic eyes, where nuclear sclerotic changes predominate. Studies indicate that 80-100% of patients experience significant development or progression within 2 years post-vitrectomy, driven by , lens exposure to oxygen, and surgical . Management typically involves monitoring lens opacity via slit-lamp examination and planning for once is affected, often combined with implantation during or after vitrectomy to preempt progression. Elevated (IOP) occurs in 20-30% of cases, commonly in the early postoperative period due to gas or , steroid use, or inflammation. This can lead to if unmanaged, with higher risks in eyes with preexisting . Prevention includes careful titration of agents and postoperative IOP monitoring; treatment involves topical beta-blockers, carbonic anhydrase inhibitors, or analogs, with or surgical intervention for refractory cases. Endophthalmitis, a rare but vision-threatening , has an incidence of 0.02-0.5% after vitrectomy, often linked to surgical wound contamination or vitreous wicks in smaller-gauge systems. Culture-positive cases occur in about 63% of instances, with symptoms including pain, , and vision loss emerging within days to weeks. Immediate management entails vitreous tap for culture, intravitreal and ceftazidime antibiotics, and repeat vitrectomy if needed, alongside systemic antibiotics to preserve function. Retinal complications include recurrent in 5-10% of cases, frequently due to missed breaks, proliferative vitreoretinopathy (PVR) scarring, or inadequate . PVR, characterized by fibrotic formation, contributes to 75% of surgical failures and develops in 5-10% of rhegmatogenous repairs. Cystoid macular edema (CME) affects 5-47% of patients, exacerbated by inflammation or emulsification, leading to central vision blurring. For recurrent and PVR, reoperation with peeling and extended is standard; CME is managed with topical nonsteroidal anti-inflammatory drugs or intravitreal corticosteroids. Corneal , occurring in up to 24% of cases in diabetic patients, results from endothelial cell loss during or prolonged hypotony, causing stromal swelling and reduced clarity. Mild cases resolve with hypertonic saline drops and observation, while persistent may necessitate endothelial keratoplasty to restore corneal transparency. Overall, vigilant postoperative monitoring, including for macular issues and tonometry for IOP, facilitates early intervention and improves prognosis.

Recovery and Postoperative Care

Immediate Postoperative Period

Following vitrectomy, patients are typically monitored closely in the immediate postoperative period, which spans the first 24 to 72 hours, to ensure stability and early detection of issues such as elevated intraocular pressure (IOP), which occurs in up to 30-50% of cases due to factors like gas tamponade or inflammation. Intraocular pressure is checked frequently, often starting in the recovery room and continuing at the day-1 follow-up visit, as spikes can peak within the first 24 hours and require prompt intervention with topical or oral pressure-lowering agents. Vision assessment is performed to evaluate for sudden changes, while patients are observed for signs of infection (e.g., increased redness, discharge, or pain) or bleeding (e.g., new floaters or vision loss). Most procedures are outpatient, allowing discharge within 1-2 hours if stable, though complex cases involving extensive retinal work or comorbidities may warrant a 1-day hospital admission for overnight monitoring. Patient instructions emphasize protective measures to support healing and prevent complications. If a gas such as 20% (SF6) or 16% perfluoroethane (C2F6) is used, face-down positioning is required for 50-90% of waking hours during the first few days to allow the bubble to seal retinal breaks effectively, with aids like specialized chairs or pillows recommended. Eye shielding with a or is advised at night or in dusty environments to avoid trauma, and activities are restricted to prevent strain: no bending at the waist beyond 90 degrees, rubbing the eye, heavy lifting over 10 pounds, or strenuous exercise for at least 48-72 hours. These precautions help minimize risks like gas-induced pressure rises or displacement. Medications are prescribed to promote and manage symptoms. Topical antibiotics, such as tobramycin-dexamethasone combinations, are administered 4 times daily for the first week to prevent , while topical steroids like are tapered over 2-4 weeks to reduce . Oral analgesics, including acetaminophen (325-1000 mg as needed) or ibuprofen (200-400 mg), address mild discomfort, which is minimal in most cases. If from anesthesia persists, anti-emetics like (4 mg IV or oral) are given prophylactically or as rescue, given the 20-40% incidence of after vitrectomy. Recent studies, including a 2025 prospective evaluation, support incorporating telemedicine for early follow-up in uncomplicated cases, suggesting remote monitoring can safely detect complications like IOP elevation or without routine in-person day-1 visits in low-risk patients. This approach enhances accessibility while maintaining safety, with virtual assessments of and symptoms showing no difference in outcomes compared to traditional care. Patients should remain vigilant for such as worsening or changes, contacting providers immediately to support progression toward long-term goals.

Long-Term Recovery

Following vitrectomy, patients typically undergo a structured follow-up schedule to monitor healing and visual progress, beginning with visits on the first day post-surgery, followed by weekly checks in the initial period, and transitioning to monthly appointments thereafter. often stabilizes within 4-6 weeks, allowing for reliable assessment of changes during this phase. Visual rehabilitation plays a key role in long-term , particularly for patients with persistent deficits. Low-vision aids, such as magnifiers or electronic devices, may be prescribed to enhance daily functioning in cases of incomplete visual restoration. In pediatric patients, therapy through exercises can help improve acuity and binocular coordination if the surgery addresses conditions like . Phakic patients require regular monitoring for development, which occurs in up to 80% of cases and often necessitates within 1-2 years post-vitrectomy. Lifestyle adjustments are essential for optimizing and preventing complications. Driving is restricted until meets legal standards, often requiring several weeks of evaluation. Patients should use UV-protective to shield the eye from light sensitivity and potential damage during outdoor activities. For those with , is recommended to reduce vascular stress and support sustained retinal health. Management of intraocular tamponades varies by type used during . Gas bubbles, such as or perfluoropropane, are typically absorbed naturally over 2-8 weeks as the eye refills with aqueous humor. tamponades require a separate removal procedure, usually scheduled 3-6 months post-vitrectomy to minimize risks like emulsification while ensuring stability. In severe cases, such as complex s, emerging investigational therapies, such as treatments in clinical trials as of 2025, show promise for promoting tissue regeneration and potentially improving visual outcomes when combined with vitrectomy.

Outcomes and Prognosis

Success Rates

Vitrectomy demonstrates high efficacy in treating various vitreoretinal conditions, with success rates varying by indication and measured by anatomical or functional outcomes. For rhegmatogenous (RRD), primary anatomical success—defined as retinal reattachment without additional surgery—ranges from 85% to 95%, while final anatomical success approaches 100% after reoperations when necessary. Functional success, typically assessed as improvement in best-corrected (BCVA) by two or more lines on the , occurs in 70% to 90% of cases, reflecting gains in visual function post-surgery. Condition-specific outcomes further highlight vitrectomy's reliability. In idiopathic full-thickness macular holes, closure rates exceed 90% when combined with internal limiting membrane (ILM) peeling, with meta-analyses confirming superior anatomical success compared to no peeling ( 9.27 for closure). Spontaneous closure without surgery is rare, occurring in approximately 11% of cases, whereas vitrectomy achieves closure in 76% to 90% based on systematic reviews. For vitreous hemorrhage, particularly in , clearance rates reach 80% to 95% within one month post-vitrectomy, enabling rapid visual rehabilitation. Recent meta-analyses and trials underscore these metrics, distinguishing anatomical from functional endpoints. A 2023 systematic review reported a 94% primary reattachment rate for tractional retinal detachment following vitrectomy (PPV). Updated data from 2024 indicate that microincision vitrectomy surgery (MIVS) enhances success rates by approximately 10% over traditional approaches through reduced trauma and faster recovery, with primary anatomical success at 93% to 97% in 27-gauge systems. Post-2023 studies have developed models for outcome prediction in RRD cases, aiding patient selection and surgical planning. Historical advancements, such as ILM techniques, have progressively elevated overall rates from 58% in early vitrectomy eras to current benchmarks.

Factors Influencing Outcomes

Several preoperative factors significantly influence the visual and anatomical outcomes of vitrectomy surgery. Preoperative best-corrected visual acuity (BCVA) is a consistent predictor of postoperative visual recovery, with better baseline acuity associated with improved final outcomes in conditions such as rhegmatogenous retinal detachment (RRD) (p < 0.001). In a study of 88 eyes undergoing pars plana vitrectomy (PPV) for RRD, preoperative BCVA showed a strong positive correlation with postoperative BCVA (p = 0.011 in multivariate analysis). Similarly, the duration of symptoms prior to surgery negatively affects prognosis; longer durations, particularly exceeding 7 days, are linked to poorer visual acuity in RRD cases (p < 0.001). Disease-specific characteristics also play a critical role. In RRD, macular status is a key determinant, with macula-on detachments yielding significantly better postoperative BCVA (logMAR 0.08) compared to macula-off cases (logMAR 0.48; p = 0.002). The presence of proliferative vitreoretinopathy (PVR) adversely impacts outcomes, correlating with worse BCVA across multiple studies (p < 0.001). (OCT) biomarkers, such as ellipsoid zone (EZ) discontinuity, further predict poorer recovery in RRD, with affected eyes showing reduced visual improvement (p = 0.024). The extent of retinal detachment, including involvement of multiple quadrants, exacerbates this risk, leading to diminished visual function postoperatively. Recent 2025 studies using AI-driven OCT analysis have shown promise in predicting visual outcomes post-vitrectomy for RRD, enhancing prognostic accuracy. For proliferative (PDR), long-term visual outcomes at 2 and 4 years post-vitrectomy are influenced by neovascular features and surgical history. The presence of and fibrovascular membranes is associated with better (≥20/40 at 2 years: OR 0.068 for absence of rubeosis, 95% CI 0.012–0.39, p = 0.003; ≥20/30 at 4 years: OR 0.078 for absence, 95% CI 0.006–0.96, p = 0.04), potentially due to earlier intervention in more severe cases. Conversely, the need for reoperation negatively predicts good outcomes (≥20/30 at 4 years: OR 0.06, 95% CI 0.07–0.54, p = 0.01). In a of 151 eyes with PDR, vitreous hemorrhage at baseline positively correlated with achieving ≥20/30 at 2 years (OR 9.55, 95% CI 1.03–95.27, p = 0.04). Intraoperative and postoperative elements, including the absence of complications like formation or , contribute to favorable results, though their impact varies by indication. Overall, early , optimized preoperative , and tailored surgical approaches mitigate adverse factors to enhance .

References

  1. [1]
    What Is Vitrectomy? - American Academy of Ophthalmology
    Oct 1, 2024 · Vitrectomy is eye surgery used to treat problems of the eye's retina and vitreous. An ophthalmologist may remove blood from inside the eye, ...
  2. [2]
    Pars Plana Vitrectomy - EyeWiki
    Sep 18, 2025 · Pars plana vitrectomy (PPV) is a commonly employed technique in vitreoretinal surgery that enables access to the posterior segment for treating conditions
  3. [3]
    Vitrectomy - National Eye Institute - NIH
    Dec 6, 2024 · During vitrectomy surgery, your eye doctor will make very small openings in your eye wall and remove most of the vitreous from your eye with a suction tool.
  4. [4]
    Retinal detachment - Diagnosis and treatment - Mayo Clinic
    Sep 27, 2024 · This surgery is known as vitrectomy (vih-TREK-tuh-me). The surgeon removes the vitreous along with any tissue that is tugging on the retina ...
  5. [5]
    Vitrectomy - StatPearls - NCBI Bookshelf - NIH
    A successful vitrectomy can restore vision and improve the quality of life in patients suffering from many vitreoretinal diseases.
  6. [6]
    Rheological Properties and Age-Related Changes of the Human ...
    Dec 18, 2018 · The vitreous is a viscoelastic gel composed of ~99% water with a framework of type II collagen and hyaluronic acid. The hyaluronic acid coils ...
  7. [7]
    Vitreous Hemorrhage - StatPearls - NCBI Bookshelf - NIH
    The vitreous humor is a transparent, colorless, jelly-like, hydrophilic gel, which helps in maintaining the transparency and structure of the eye.
  8. [8]
    Phacoemulsification - StatPearls - NCBI Bookshelf
    Phacoemulsification is a modern cataract surgery first developed by Charles Kelman in 1967. The discovery of phacoemulsification came as a boon for the medical ...
  9. [9]
    EARLY DESCRIPTIONS OF VITREOUS SURGERY - PubMed
    Jul 1, 2021 · In English literature, the first description of vitrectomy is attributed to the American surgeon John Collins Warren (1778-1856). This ...Missing: 1680 1840<|separator|>
  10. [10]
    Vitrectomy - Milestones In Retina
    [24] Specifically, in 1983, Steve Charles and Carl Wang designed the first single pulse cut and spring return disposable vitreous cutting probe, which was one ...
  11. [11]
    The History of Vitrectomy: Innovation and Evolution - Retina Today
    Robert Machemer developed closed, pars plana vitrectomy to eliminate the need for keratoplasty and operate with a closed system with controllable intraocular ...
  12. [12]
    An Update on Surgical Viewing Systems - Review of Ophthalmology
    Jun 8, 2020 · As detailed in the sidebar on page 68, the development of the first non-contact viewing system—the BIOM—in 1987 provided an alternative to ...
  13. [13]
    Vitreoretinal instruments: vitrectomy cutters, endoillumination and ...
    Dec 5, 2016 · This article will review some advances in vitrectomy technology focusing on vitreous cutters, endoillumination and wide-angle viewing systems.
  14. [14]
    Recent developments in imaging and surgical vision technologies ...
    Jul 3, 2023 · The main aim of this review is to update the reader on the latest progression in intraoperative imaging and surgical vision technologies.
  15. [15]
    AI for the vitreoretinal surgeon - Retina Specialist
    Mar 20, 2023 · Surgical planning and navigation: AI can be used to assist in surgical planning by analyzing images of the eye and creating a personalized ...
  16. [16]
    Artificial Intelligence, Digital Imaging, and Robotics Technologies for ...
    Jan 25, 2024 · Artificial intelligence was also able to predict anatomical outcomes after RD treatment. Fung et al predicted surgical outcomes of RD repair.Novel Imaging Technologies... · Widefield Fundus Photography · Ai For Surgical Vr Diseases
  17. [17]
    Surgical Management of Diabetic Retinopathy - PMC - NIH
    INDICATIONS AND OUTCOMES FOR PARS PLANA VITRECTOMY IN DIABETIC RETINOPATHY · Vitreous hemorrhage · Tractional retinal detachment · Combined tractional and ...
  18. [18]
    Vitreous Hemorrhage - EyeWiki
    Primary Prevention. Primary prevention should be directed at controlling risk factors for systemic vascular disease such as diabetes, hypertension, and smoking.
  19. [19]
    Five Tips for Coding Vitrectomy Surgeries - Retina Today
    With more than 225,000 performed each year in the United States, pars plana vitrectomy (PPV) is an essential part of any surgical vitreoretinal practice—and its ...Missing: annually | Show results with:annually
  20. [20]
    Managing Vitreous Floaters - Retina Today
    Vitrectomy is a safe and effective treatment for VDM and can normalize contrast sensitivity within 1 week of surgery. Researchers are investigating the use of ...
  21. [21]
    Vitrectomy for Floaters - The American Society of Retina Specialists
    Outpatient surgery with local anesthesia can be utilized during vitrectomy to remove floaters and vitreous debris. During this procedure, nearly all the ...
  22. [22]
    [PDF] Diabetic Retinopathy Preferred Practice Pattern®
    Sep 13, 2024 · The Diabetic Retinopathy PPP was sent for review in July 2024 to improve the quality of the guideline, to gather.
  23. [23]
    Risk of Systemic Health Events and Mortality After Vitrectomy ... - NIH
    Jul 7, 2025 · DR Requiring Vitrectomy vs.​​ Patients with DR requiring PPV showed a substantially higher risk of negative systemic health events than diabetics ...
  24. [24]
    Long-Term Mortality in Diabetic Patients with Tractional Retinal ...
    Patients with diabetic TRD requiring vitrectomy surgery have an alarming 48.7% long-term, all-cause mortality rate over 10 years, with a mean survival of 2.7 ...
  25. [25]
    Pars Plana Vitrectomy: Overview, Indications, Contraindications
    Jan 9, 2023 · In these conditions, the procedure may be contraindicated only if the eye has no light perception and if regaining any vision in the eye is ...
  26. [26]
    Guidelines for preoperative visual function and imaging examination ...
    May 18, 2025 · This guideline seeks to thoroughly investigate the standardized operational procedures for visual function and imaging examinations prior to vitreoretinal ...
  27. [27]
    Recommendations for Genetic Testing of Inherited Eye Diseases
    The Academy's Task Force report on genetic testing that provides guidance on the underlying principles and approaches of genetic testing.
  28. [28]
    Hereditary Vitreoretinopathies: Molecular Diagnosis, Clinical ... - NIH
    Hereditary vitreoretinopathies (HVRs), also known as hereditary vitreoretinal degenerations comprise a heterogeneous group of inherited disorders of the retina ...
  29. [29]
    Genotypic Distribution and Clinical Correlations in Familial ...
    Mar 28, 2025 · Patients identified with abnormal peripheral retinal or intra- vitreal vascularization were recommended for genetic testing. Next-generation ...
  30. [30]
    Shared decision-making and choice for elective surgical care
    SDM reduces decision conflict and improves decision quality for patients making choices about elective surgery.
  31. [31]
    Who Knows Best? The Challenges of Shared Decision Making
    Dec 1, 2012 · How to address complex issues such as off-label drugs, new technologies, and costs in discussing treatment options with your patients.
  32. [32]
    Anesthesia in Vitreoretinal Surgery - EyeWiki
    Jan 27, 2025 · 2 Anesthesia Techniques. 2.1 General Anesthesia; 2.2 Sedation with local anesthesia (subconjunctival/retrobulbar/peribulbar/sub-tenon blocks).Missing: types pros
  33. [33]
    Anesthesia for Eye Surgery - StatPearls - NCBI Bookshelf
    Aug 25, 2023 · Regional anesthesia via nerve blockade is usually accomplished via the retrobulbar, peribulbar, or sub-Tenon (episcleral) block. The sub-Tenon ...Missing: vitrectomy pros
  34. [34]
    Sub-Tenon versus peribulbar anesthesia in vitreoretinal surgery
    Sub-Tenon anesthesia is a simple, safe, and less traumatic technique that is as good as peribulbar in terms of providing analgesia.
  35. [35]
    Vitrectomy - Patients - The American Society of Retina Specialists
    Vitrectomy is a surgical procedure undertaken by a specialist where the vitreous humor gel that fills the eye cavity is removed to provide better access to the ...Missing: NEI | Show results with:NEI
  36. [36]
    Choosing Wisely: Antibiotic Use in Ophthalmic Surgery - Retina Today
    Regarding vitreoretinal surgery, no antibiotics should be given preoperatively. Routine antibiotics are unnecessary postoperatively after routine (ie, ...
  37. [37]
    How to Perform an Anterior Vitrectomy
    Apr 1, 2006 · The goals of anterior vitrectomy are to remove the vitreous from the anterior chamber, to clear any vitreous from the entry incisions and to ...
  38. [38]
    Review of Small Gauge Vitrectomy: Progress and Innovations - PMC
    Mar 29, 2017 · Retinal specialists have shifted away from 20G systems to smaller sutureless systems that have reduced operative times, surgical trauma, ...
  39. [39]
    Pars Plana Vitrectomy Alone or Combined with Phacoemulsification ...
    A combination of phacoemulsification with PPV affords certain advantages, including better visualization during retinal surgery and wider access to the vitreous ...
  40. [40]
    Advancements in robotic surgery for vitreoretinal diseases
    Aug 1, 2025 · In recent years, the use of AI in surgery has been expected. Examples of the use of AI in surgery include preoperative and intraoperative ...
  41. [41]
    Refining vitrectomy for proliferative diabetic retinopathy - PMC
    Jun 14, 2023 · Pars plana vitrectomy (PPV) is the main treatment modality for patients with severe diabetic retinopathy. With the development of systems ...
  42. [42]
    Vitrectomy Basics - VBS Academy
    The core vitrectomy is usually the first step of the surgery and serves to debulk the central gel. It is important to keep the eye well centered and to use the ...
  43. [43]
    How To Perform the Lift-and-Shave Technique - Retina Today
    Perform a core vitrectomy and remove all of the peripheral vitreous. ... If postoperative vitreous hemorrhage occurs, perform an in-office fluid-air exchange.
  44. [44]
    Surgical Contact Lenses - Volk Optical
    30-day returnsDesigned to work seamlessly in every surgical interface, our surgical vitrectomy lenses deliver crisp views, enabling you to focus on precise surgical tasks.
  45. [45]
    A new, non-contact wide field viewing system for vitreous surgery
    A new, noncontact wide field viewing system for vitreoretinal surgery has been developed with satisfactory image quality and a field of view comparable to ...
  46. [46]
    Heads-Up Three-Dimensional Viewing Systems in Vitreoretinal ...
    Aug 28, 2023 · Three-Dimensional (3D) heads-up visualization systems have significantly advanced vitreoretinal surgery, providing enhanced detail and improved ergonomics.
  47. [47]
    Three-Dimensional Visualization System for Vitreoretinal Surgery
    Oct 13, 2025 · Conclusions: In our experience, a heads-up 3D surgical viewing system provided comparable functional and anatomical outcomes in comparison with ...
  48. [48]
    Advancements in robotic surgery for vitreoretinal diseases
    Aug 1, 2025 · In cataract surgery, robots using femtosecond lasers have been developed, making safer and more reliable surgery possible. However, at ...
  49. [49]
    Intraoperative OCT-Guided Selective Epiretinal Membrane (ERM ...
    Nov 21, 2024 · We compared the safety and effectiveness of intraoperative optical coherence tomography (iOCT)-assisted selective epiretinal membrane (ERM) ...
  50. [50]
    Chapter-16 Hemostasis during Vitreoretinal Surgery - JaypeeDigital
    Intraoperative hemorrhage is a major concern during vitrectomy particularly when active fibrovascular proliferative membranes are encountered.<|separator|>
  51. [51]
    Control of Perioperative Bleeding in Vitreoretinal Surgery
    The first and most common method of stopping the bleeding is by raising the IOP through manipulation of the infusion line pressure [17].
  52. [52]
    Managing Surgical Complications in Retina Surgery
    For small suspected retrobulbar hemorrhages, the infusion pressure can be pulsed to higher pressures periodically during vitrectomy to help tamponade and ...
  53. [53]
    Iatrogenic Retinal Breaks Complicating Pars Plana Vitrectomy
    The incidence of peripheral breaks was 4% and of posterior breaks was 6%. Patients with proliferative diabetic retinopathy had a higher incidence of iatrogenic ...Missing: tears | Show results with:tears
  54. [54]
    Iatrogenic Retinal Breaks in 20-G versus 23-G Pars Plana Vitrectomy
    Sclerotomy-related retinal breaks occurred in 50/628 (7.9%) of 20-G PPV and 5/296 (1.7%) of 23-G PPV (p<0.0001). Anterior (non-sclerotomy) retinal breaks ...
  55. [55]
    Complications of Vitreoretinal Surgery - Review of Ophthalmology
    Jan 24, 2008 · Though rare, retrobulbar anesthesia complications can occur (See Figure 1). One review reported a 0.08 percent incidence of globe penetration in ...
  56. [56]
    The State of Intraoperative OCT in Vitreoretinal Surgery - NIH
    Sep 1, 2023 · This narrative review aims at describing the state of the art of iOCT in vitreoretinal procedures, highlighting its modern role and applications ...Missing: mitigation risks
  57. [57]
    Glaucoma and High IOP After Vitreoretinal Procedures
    Aug 1, 2023 · The incidence of elevated IOP after uncomplicated pars plana vitrectomy (PPV) ranges from 15% to 20%, and the rates have been higher for PPV in ...
  58. [58]
    Cataract Formation after Pars Plana Vitrectomy
    Jul 19, 2016 · Several studies have shown cataract progression in 80-100% of patients at 2 years follow-up. Nuclear sclerosis is the most common type of cataract following ...
  59. [59]
    Cataract Surgery After Vitrectomy/Phacovitrectomy - EyeWiki
    Sep 30, 2025 · The risk of “lens touch” during an intraocular procedure has been associated with the rapid development of cataracts postoperatively. In a large ...
  60. [60]
    Elevated Intraocular Pressure Associated with Retinal Procedures
    Mar 26, 2025 · Elevated IOP is a common complication following pars plana vitrectomy. ... chamber pressure build-up without angle-closure. Secondary ...<|separator|>
  61. [61]
    INCIDENCE OF ENDOPHTHALMITIS AFTER VITRECTOMY - PubMed
    The incidence of endophthalmitis after 20 G vitrectomy was 0.04% (88/229,435), compared with 0.03% (8/27,326) after 23 G and 0.11% (33/29,676) after 25 G.
  62. [62]
    Endophthalmitis after Pars Plana Vitrectomy - Ophthalmology Retina
    Feb 28, 2025 · The overall incidence of post-PPV endophthalmitis was 0.05% (n ¼ 19), of which 63.2% (n ¼ 12) were culture positive.
  63. [63]
    Proliferative Vitreoretinopathy - Colorado Retina Associates
    Jun 17, 2024 · PVR accounts for 75% of problems following RD surgery. PVR occurs in 5-10% of patients after having retinal reattachment surgery. PVR occurs ...
  64. [64]
    Proliferative Vitreoretinopathy: A Reappraisal - MDPI
    Aug 14, 2023 · The incidence of recurrent retinal detachment due to PVR is higher within the first three months after surgery, with 77% of cases occurring ...<|separator|>
  65. [65]
    Manage macular edema after PPV
    Aug 1, 2018 · The incidence of post-vitrectomy macular edema can range anywhere from 5% to 47%,- but determining whether the vitrectomy itself causes ...
  66. [66]
    Challenges in proliferative vitreoretinopathy: is biological therapy a ...
    Animal models have shown that ranibizumab, an anti-VEGF biological drug, effectively reduced PVR incidence in rabbits [24]; nevertheless, clinical studies have ...
  67. [67]
    [PDF] Factors Contributing to Corneal Complications After Vitrectomy in ...
    Results: Of the 202 eyes, 102 (50.5%) developed corneal complications after surgery; 90. (44.6%) had epithelial disturbance; and 48 (23.8%) had corneal edema.
  68. [68]
    Elevation in intraocular pressure following vitreoretinal surgery
    [6] Hence post vitreoretinal surgery IOP monitoring becomes very important both in the immediate postoperative period and in the long-term. In those with a ...<|separator|>
  69. [69]
    Cataract, Cornea, and Retina Surgeries: Strategies to Manage ...
    Jun 1, 2021 · Patients should also avoid postoperative exposure to nitrous oxide gas until resorption. The gas is highly soluble and quickly diffuses into the ...
  70. [70]
    Is day-1 postoperative review necessary after pars plana vitrectomy?
    Aug 28, 2015 · The intervention rate on the first day after vitrectomy is low and day-1 postoperative review can be safely omitted in the majority of patients ...
  71. [71]
    Face-Down Recovery After Retinal Surgery
    Oct 24, 2024 · You must stay face down at all times, unless your eye surgeon tells you otherwise. This means staying face down when you stand, sit, eat, walk, ...Missing: immediate | Show results with:immediate
  72. [72]
    [PDF] Retina Surgery Post-Operative Instructions
    Discomfort after vitrectomy is minimal. Patients are advised to use Advil (200-400 mg) or. Tylenol (325 – 1000 mg) if needed.
  73. [73]
    Rise in intraocular pressure with elevator travel in post-vitrectomy ...
    Aug 28, 2023 · Patients undergoing vitreoretinal surgery with gas insertion had statistically significant intraocular pressure rise even with 8-floor ascent in the immediate ...Missing: monitoring | Show results with:monitoring
  74. [74]
  75. [75]
    Efficacy of Three Different Prophylactic Treatments for Postoperative ...
    Mar 21, 2019 · Efficacy of three different prophylactic treatments for postoperative nausea and vomiting after vitrectomy: a randomized clinical trial.
  76. [76]
    Prospective Telemedicine Postoperative Protocol Following ...
    Telemedicine-assisted POV may be a safe and convenient alternative for patients undergoing uncomplicated MIVS, but additional and larger studies are needed.Missing: 2024 | Show results with:2024
  77. [77]
    Patient Guide to Vitrectomy Surgery | Mahajan Laboratories
    Apr 19, 2019 · Follow-up appointments are generally scheduled one day, one week, and one month after surgery. Most stitches dissolve on their own after a month ...Missing: refraction | Show results with:refraction
  78. [78]
    [PDF] Planning for Vitrectomy - Blue Coast Retina
    • In most cases we will see you again one week, one month and three months after surgery. This outline can change depending on the reason for surgery and ...
  79. [79]
    Refractive stability and timing of spectacle prescription following ...
    Feb 14, 2024 · The results of the present study found that post-operative refractive stabilisation could be achieved within 1 week. Nevertheless, only 4.3% of ...
  80. [80]
    Low Vision Rehabilitation for Macular Degeneration
    Low vision rehabilitation can help people with vision loss from macular degeneration maintain independence and quality of life. Learn more.
  81. [81]
    [PDF] Recovery and rehabilitation after retinal detachment surgery.
    Sep 26, 2024 · Vision therapy may be beneficial for patients with residual amblyopia or binocular vision dysfunction following retinal detachment surgery, Low ...<|control11|><|separator|>
  82. [82]
    Recovery and Rehabilitation Following Macular Hole Surgery.
    Oct 25, 2024 · Wearing sunglasses outside is vital for protecting your healed eye from harsh light and UV radiation. Additionally, avoid touching or pushing on ...
  83. [83]
    Diabetic Retinopathy Surgery Recovery- Timeline, Diet, & Lifestyle ...
    Quit Smoking: Smoking can damage blood vessels and increase the risk of developing diabetic retinopathy or other eye conditions. Quitting smoking can help ...
  84. [84]
    Refinements in the use of silicone oil as an intraocular tamponade
    Mar 28, 2024 · Gaseous intraocular tamponades undergo spontaneous resolution by absorption into the blood stream (their volume being taken up by aqueous phase) ...
  85. [85]
    Top Five Pointers for Working With Silicone Oil - Retina Today
    The optimal timing for silicone oil removal is not universally agreed upon, but many surgeons recommend a minimum of 3 to 6 months of intraocular tamponade ...Missing: absorption | Show results with:absorption
  86. [86]
    Retinal Detachment Surgery: New Ideas Improving Vision Recovery
    Feb 7, 2025 · 4. Gene and Stem Cell Therapy. These treatments show promise for healing injured retinal cells and enhancing post-operative vision even in ...
  87. [87]
    Success Rates of Vitrectomy in Treatment of Rhegmatogenous ... - NIH
    The primary anatomical success of PPV for primary uncomplicated RRD was 89.8% and the final anatomical success rate was 100%.
  88. [88]
    Proportion of Eyes with Visual-Acuity Improvement after Vitrectomy ...
    Sep 23, 2025 · Vitrectomy for PTE often yielded visual improvement, particularly in adults, while ambulatory vision (≥20/200) was less common. Given the single ...
  89. [89]
    Prediction of Visual Outcomes After Diabetic Vitrectomy Using ...
    At 1 year after vitrectomy, vision was 20/40 or better in 586 eyes (39.0%). During the year after surgery, 1188 eyes (78.9%) experienced improved or consistent ...
  90. [90]
    A delphi consensus study for treatment of full-thickness macular hole ...
    Jul 1, 2025 · Advancements in vitrectomy and internal limiting membrane (ILM) manipulation have substantially improved closure rates of more than 90% and ...
  91. [91]
    Comparison of ILM peeling vs. inverted ILM flap for macular hole ...
    Jul 17, 2025 · In this meta-analysis study, from 12 RCTs, the primary outcome of anatomical closure was significantly greater than that of ILM peeling, ...
  92. [92]
    Vitrectomy vs. Spontaneous Closure for Traumatic Macular Hole
    Dec 22, 2021 · In this systematic review, the TMH closure rate ranges from 0.63 to 1.0 with a pooled event rate of 0.90, while the VA improvement rate ranges ...
  93. [93]
    A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Aug 15, 2023 · The mean BCVA at one month was significantly better in the vitrectomy group (MD=0.22, CI:0.10–0.34, p=0.0003), but no difference was found at ...
  94. [94]
    Comparison of outcomes of four different treatment modalities for ...
    Feb 28, 2020 · We conducted this study to analyse the visual outcomes and VH clearance rates ... Non-clearing vitreous haemorrhage was main cause of poor visual ...<|separator|>
  95. [95]
    Outcomes and Complications of Pars Plana Vitrectomy for Tractional ...
    Jan 12, 2023 · This systematic review and meta-analysis investigates the outcomes of pars plana vitrectomy for the treatment of diabetic tractional retinal ...
  96. [96]
    Comparison of 27-Gauge to 25-Gauge Vitrectomy in Patients ... - MDPI
    The primary anatomical success was 88% in the 25G and 97% in the 27G groups (p > 0.05). The risk factors for a postoperative retinal detachment were ...
  97. [97]
    Comparison of 27‐Gauge and 25‐Gauge Microincision Vitrectomy ...
    Aug 18, 2020 · The primary anatomical success rate after a single operation was 91.6% and 93.3% in the 25-G and 27-G groups, respectively (Figure 5). The ...
  98. [98]
    A Review of Surgical Outcomes and Advances for Macular Holes - NIH
    Following the introduction of vitrectomy by Kelly and Wendel [5], the closure rate increased to 58%. As surgical techniques and instrumentation have improved, ...
  99. [99]
    Prognostic Factors for Visual Postsurgical Outcome in ...
    Mar 16, 2025 · The factors that significantly influenced postoperative prognosis in RRD included preoperative best-corrected visual acuity (BCVA), duration of symptoms, ...
  100. [100]
    Prognostic Factor Analysis of Visual Outcome after Vitrectomy for ...
    Oct 12, 2020 · The influence of the patients' age, duration of symptoms, preoperative BCVA, axial length, lens status, macular status (on/off) and the presence ...
  101. [101]
    Factors correlated with visual outcomes at two and four years after ...
    Jan 14, 2021 · This study aimed to reveal the factors correlated with better postoperative visual acuity after a long follow-up in patients who underwent vitrectomy for PDR.